At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 8 enrolled
Drug / intervention
Crinecerfontdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal Hyperplasia
In Brief
A Phase 2 clinical trial evaluating Crinecerfont for CAH - Congenital Adrenal Hyperplasia. Completed, enrolled 8 participants across 6 sites.
Detailed Summary
This is a Phase 2, open-label, multiple-dose, study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NBI-74788 (crinecerfont) in pediatric participants (14 to 17 years of age) with a documented medical diagnosis of classic 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCAH - Congenital Adrenal Hyperplasia
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartDec 2019
Primary CompletionJul 2021
TodayJul 2026
First PostedAug 5, 2019
Enrollment StartDec 12, 2019
Primary CompletionJul 2, 2021
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.9 years ago
Interventions
Crinecerfontdrug
Crinecerfont administered orally for 14 consecutive days.